News ABVC BioPharma, Inc.

Equities

ABVC

US00091F3047

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.42 ^USD	-10.69%		+43.42%	+22.41%

Apr. 10	ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc	CI
Mar. 26	ABVC BioPharma, Inc. and BioFirst Corporation Enter Global Licensing Agreement with ForSeeCon Eye Corporation	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share	Apr. 18	AQ
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M	Apr. 17	AQ
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M	Apr. 10	AQ
ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc	Apr. 10	CI
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M	Mar. 26	AQ
ABVC BioPharma, Inc. and BioFirst Corporation Enter Global Licensing Agreement with ForSeeCon Eye Corporation	Mar. 26	CI
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars	Mar. 21	AQ
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine	Mar. 19	AQ
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update	Mar. 14	AQ
ABVC BioPharma : Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update - Form 8-K	Mar. 14	PU
ABVC BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
ABVC BioPharma Signs Licensing Deal With Senior Paradise	Feb. 15	MT
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues	Feb. 15	AQ
ABVC BioPharma, Inc. Executes a Definitive Agreement to Receive License Fees of $3 Million and Royalties of 2% on Future Revenue	Feb. 15	CI
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)	Feb. 12	AQ
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share	Feb. 08	AQ
ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC	Jan. 16	CI
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI	Jan. 08	AQ
Top Premarket Decliners	Jan. 04	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	Jan. 03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ABVC BioPharma, Inc.

Equities

ABVC

US00091F3047

Summary

Filters